Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.64 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.64 |
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.46 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.46 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.46 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | F11 | P03951 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399139 | 0.88 | ORAI1 (0.64) | LPLLIPGCA2KCNH2AGXT | |
| SCHEMBL12270601 | 0.86 | KCNH2 (0.47) | LPLLIPGCA2KCNH2AGXT | |
| SCHEMBL2553625 | 0.83 | MAOB (0.58) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL16687435 | 0.83 | MAOB (0.58) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL3161372 | 0.82 | AGXT (0.64) | CA2KCNH2AGXTCA1CA9 | |
| SCHEMBL9617939 | 0.82 | AGXT (0.64) | CA2KCNH2AGXTCA1CA9 | |
| SCHEMBL16151496 | 0.82 | TRPV6 (0.55) | LPLLIPGCA2KCNH2AGXT | |
| SCHEMBL13978537 | 0.82 | LPL (0.59) | LPLLIPGCA2CA1F11 | |
| SCHEMBL178228 | 0.82 | TSHR (0.62) | LPLLIPGCA2CA1F11 | |
| SCHEMBL12011034 | 0.81 | LPL (0.73) | LPLLIPGCA2KCNH2ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | FAAH, FAAH2, ASAH1 | LPL 163/4885LIPG 304/4885CA2 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.